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Microarray(−)-Epigallocatechin-3-gallate (EGCG) is one of the most potent and the most studied green tea catechin. Re-
ports on mechanisms of EGCG action and its cellular targets are plenty. Compelling evidences in the literature
in favor of ER being one of its targets suggest that EGCG may have a signiﬁcant impact on estrogen regulated
gene expression. Despite the possible implications on breast cancer chemoprevention or therapy, this aspect of
EGCG action has not been adequately investigated. In order to address this issue, we have obtained gene expres-
sion proﬁles of MCF-7 breast cancer cells treatedwith ethanol (vehicle control) and those treated with estrogen,
EGCG or both, using microarrays. Here, we have presented in detail the design and execution of the microarray
experiment, quality control checks and analysis of microarray data. The utility and importance of the data gener-
ated in this work have been discussed in the context of the background literature. Our data is available in the
Gene Expression Omnibus (GEO) database with the identiﬁer GSE56245.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell line/tissue Homo sapiens/ER-positive MCF-7 breast cancer cell line
Sex Female
Sequencer or array type Agilent's human gene expression study 8 × 60 K
microarray slides (AMADID:27114)
Data format Raw and processed
Experimental factors MCF-7 cells treated with 17β-estradiol, EGCG or both.
Experimental features Total RNA samples isolated fromMCF-7 cells treated with
17β-estradiol (10 nM), EGCG (40 μM) or both for a period
of 24 h were subjected to microarray analysis using the
Agilent platform. Total RNA from cells treated with
ethanol (vehicle) served as controls. Eight hybridizations
(one color) with eight total RNA samples were carried
out. These comprised of total RNA samples from two
experimental replicates each of 17β-estradiol, EGCG,
17β-estradiol + EGCG, and ethanol treated cells.Consent N/A
Sample source location Guwahati, Assam, India1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE56245.. This is an open access article under2. Experimental design, materials and methods
2.1. Cell culture
The ER-positive human breast cancer cell line, MCF-7, was
routinely cultured in 25 cm2 ﬂasks (Greiner Bio-One, GmbH,
Germany), under standard culture conditions (37 °C, 5% CO2), in
phenol red containing DMEM-F12 supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 units/ml of penicillin and
100 μg/ml of streptomycin (M1). Once conﬂuent, the cells were
trypsinized and split into fresh 25 cm2 ﬂasks in a ratio of 1:3 for ex-
pansion. Else, the cells were seeded in 35 mm dishes (2 × 105 cells
per dish) using M1 for experimentation.
2.2. Experimental protocol
Once the 35 mm dishes were 60–70% conﬂuent, M1 was replaced
with phenol red-free DMEM-F12 supplemented with 10% charcoal
stripped heat-inactivated FBS, 100 units/ml of penicillin and 100 μg/ml
of streptomycin (M2), and allowed to grow for 4 h. Spent M2 was
then replaced with fresh M2 containing ethanol (vehicle), 10 nM of
17β-estradiol (E2), 40 μM of EGCG, or both and incubated further for a
period of 24 h before harvesting the cells for total RNA extraction.
Thus, the experiment comprised of four treatment groups including
the vehicle control. Two dishes (biological replicates for the microarraythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Quality control of Cy3 incorporation in the labeled RNA.
Sample
codesa
Cy3
(pmol/μl)
Concentration of
labeled RNA (ng/μl)
Absorbance
260/280
Speciﬁc activity
pmol dye/μg cRNA
C1 1.67 167.56 2.26 9.97
C2 1.02 115.87 2.34 8.80
E1 1.80 176.40 2.28 10.20
E2 1.83 165.75 2.28 11.04
X1 2.25 196.64 2.29 11.44
X2 2.16 202.70 2.31 10.66
EX1 2.01 193.02 2.35 10.41
EX2 1.08 126.66 2.34 8.53
a C1 & C2—vehicle treated, E1 & E2—10 nM of 17β-estradiol, X1 & X2—40 μM of EGCG,
EX1 & EX2—combined treatment with the 10 nM of 17β-estradiol and 40 μM of EGCG.
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trations of E2 and EGCG were optimized earlier [1]. The effectiveness
of 10 nM of E2 was conﬁrmed based on the induction of steady state
mRNA levels of two estrogen induced genes, namely trefoil factor-1
(pS2) and progesterone receptor (PR). EGCG at 40 μM concentration
was ideally suited for this experiment, since it caused only a modest
(20%) reduction in viability of MCF-7 cells. Under this condition the
modulation in gene expression by EGCG could safely be interpreted as
primary, and not as a collateral effect of cyotoxicity observed at high
concentrations [1].
At the end of the experiment, the cells were lysed in RLT buffer
(RNeasy kit, Qiagen, GmbH, Germany). Lysates were sent to Genotypic
Technology (P) Ltd., Bangalore, India for total RNA extraction, labeling,
hybridization, image acquisition, quality control and primary analysis
of raw intensity data.
2.3. RNA isolation, labeling, hybridization and image acquisition
RNeasyMini Kit (Qiagen, GmbH, Germany)was used to extract total
RNA. RNA concentrations were determined based on absorbance at
260 nm wavelength of light. The quality of RNA was assessed on 2100
Bioanalyzer (Agilent, Paulo Alto, CA, USA). RNA samples were consid-
ered to be of good quality if they satisﬁed the following criteria —
a) A260/A280 ratio N1.8, b) A260/A230 ratio ≥1.5, and c) 28S/18S inten-
sity ratio N1.5. All our total RNA samples satisﬁed these criteria. The RNA
quality control data are provided in Table 1.
For each sample, 500 ng of total RNA was labeled (one color with
Cy3) using Agilent's Low Input RNA linear ampliﬁcation kit (Cat No.
5188–5339). The labeled complementary RNAs were puriﬁed using
RNeasy Mini Kit, checked for quality (Table 2) and hybridized to
Agilent's human gene expression study 8 × 60 K microarray slides
(AMADID:27,114), using the Agilent's in situ hybridization kit (Cat
No. 5184–3568). Following hybridization and washes, the images
were scanned in microarray scanner (Model G2565BA, Agilent).
The raw intensity data was extracted using Agilent's Feature Extrac-
tion Software.
2.4. Assessment of image quality
The images were manually checked for uneven hybridizations,
streaks, blobs and other artifacts. Images were found to be clean with
low background noise. Microarray images and signal statistics for each
array are provided as supplementary information in Appendices A and
B, respectively.
2.5. Microarray data analysis
For data analysis we used LIMMA package from Bioconductor [2].
Background correction was performed using “normexp” method in
LIMMA with an offset of 16 [3]. The “quantile” method was used for
normalization of the data between arrays. Further, the “avereps” func-
tion was used to average replicate spots. We applied “lmﬁt” (linear
model) and “eBayes” (Empirical Bayes method) for determination ofTable 1
Total RNA quality control.
Sample codesa Absorbance value 260/280 Absorbance value 260/230 RNA conc
C1 2.1 2.2 324.3
C2 2.1 1.5 260.1
E1 2.1 2.2 336.3
E2 2.1 2.2 337.4
X1 2.1 2.2 359.1
X2 2.1 2.2 410.2
EX1 2.1 1.9 283.6
EX2 2.1 2.2 338.7
a C1 & C2—vehicle treated, E1 & E2—10 nM of 17β-estradiol, X1 & X2—40 μM of EGCG, EX1differentially regulated genes. The R code used for processing of the
data is as follows:
Library (limma)
Targets=readTargets(“targets.txt”)
x=read.maimages(targets, source=“agilent”, green.only=TRUE)
y=backgroundCorrect(x, method=“normexp”, offset=16)
y=normalizeBetweenArrays(y, method=“quantile”)
y.ave=avereps(y, ID=y$genes$ProbeName)
f=factor(targets$Condition, levels=unique(targets$Condition))
design=model.matrix(~0+f)
colnames(design)=levels(f)
ﬁt=lmFit(y.ave, design)
contrast.matrix=makeContrasts(“E-C”, “X-C”, “EX-C”, levels=
design)
ﬁt2=contrasts.ﬁt(ﬁt, contrast.matrix)
ﬁt2=eBayes(ﬁt2)
output=toptable(ﬁt2, adjust=“BH”, coef=“E-C”, genelist=
y.ave$gene, number=Inf)
write.table(output, ﬁle=“E-C.txt”, sep=“\t”, quote=FALSE)
output1=toptable(ﬁt2, adjust=“BH”, coef=“X-C”, genelist=
y.ave$gene, number=Inf)
write.table(output1, ﬁle=“X-C.txt”, sep=“\t”, quote=FALSE)
output2=toptable(ﬁt2, adjust=“BH”, coef=“EX-C”, genelist=
y.ave$gene, number=Inf)
write.table(output2, ﬁle=“EX-C.txt”, sep=“\t”, quote=FALSE).3. Discussion
An inverse correlation between green tea consumption and breast
cancer risk is apparent from the results of epidemiological studies
[4–6]. The widespread interest in the major green tea polyphenol,
EGCG, as a chemopreventive and chemotherapeutic agent against
breast cancer stems from a substantial amount of data available through
experimental studies using cell culture and animalmodels of breast car-
cinogenesis [7–10]. Molecular targets of EGCG have also been identiﬁed
[11]. However, despite the fact thatmajority of breast tumors at diagno-
sis are estrogen dependent and ER positive, the impact of EGCG onentration (ng/μl) Total yield (ng) QC purity QC conc./yield QC integrity
6485.6 Optimal Optimal Good
5202.6 Optimal Optimal Good
6726.0 Optimal Optimal Good
6747.6 Optimal Optimal Good
7182.6 Optimal Optimal Good
8204.2 Optimal Optimal Optimal
5671.0 Optimal Optimal Good
6773.6 Optimal Optimal Good
& EX2—combined treatment with the 10 nM of 17β-estradiol and 40 μM of EGCG.
Table 3
A summary of number of probes modulated by E2, EGCG and both.
Treatmenta Total number of probes
showing modulationb
Number of probes
showing induction
Number of probes
showing repression
E2 3411 1689 1722
EGCG 3317 1844 1473
E2 + EGCG 9183 4998 4185
a The concentrations used are 10 nM for E2 and 40 μM for EGCG.
b The number of probes showing modulation with respect to vehicle treated control.
Fig. 1. Venn diagram showing the number of probes regulated by the indicated treat-
ments. The concentrations used are 10 nM for E2 and 40 μM for EGCG.
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not been addressed.
Taking a cue from earlier studies which suggest that EGCG can inﬂu-
ence estrogen regulated gene expression [12–15], we also demonstrat-
ed EGCGmediated increase inmRNA levels of the two estrogen induced
transcripts, namely pS2 and PR [1]. The microarray experiment
described in this report seeks to address the impact of EGCGon estrogen
regulated gene expression at the genome-wide scale. The results of the
basic analysis of differentially expressed genes by the treatments with
respect to control are presented in Table 3 and Fig. 1. While on one
hand there are genes exclusively modulated by each of the treatments,
on the other hand a considerable overlap of genes between the treat-
ment groups is also apparent from the data.
This work and the resulting data is a small but signiﬁcant step to-
wards understanding the mechanism of EGCG action. A comprehensive
analysis of the microarray data generated in this study will be useful in
obtaining insights into EGCG mediated modulation of estrogen driven
processes in ER-positive breast cancer cells. This in turn will help in
judging the true potential of EGCG as a chemopreventive or chemother-
apeutic agent against breast cancer.
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